Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.

[1]  J. Lechner-Scott,et al.  Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry , 2022, Multiple sclerosis.

[2]  D. Centonze,et al.  Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study , 2022, Neurology and Therapy.

[3]  H. Butzkueven,et al.  The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets , 2022, Current medical research and opinion.

[4]  M. Soilu-Hänninen,et al.  Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. , 2022, Multiple sclerosis and related disorders.

[5]  T. Ziemssen,et al.  Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany , 2022, Journal of Neurology.

[6]  X. Montalban,et al.  Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. , 2020, Multiple sclerosis and related disorders.

[7]  J. Rassen,et al.  Graphical Depiction of Longitudinal Study Designs in Health Care Databases , 2019, Annals of Internal Medicine.

[8]  G. Giovannoni,et al.  Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers , 2019, Therapeutic advances in neurological disorders.

[9]  A. Ghezzi.  European and American Guidelines for Multiple Sclerosis Treatment , 2018, Neurology and Therapy.

[10]  Abidemi K. Adeniji,et al.  Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study , 2018, Multiple sclerosis.

[11]  J. Lechner-Scott,et al.  Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis , 2018, Multiple sclerosis.

[12]  G. Harty,et al.  Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis , 2018, Current medical research and opinion.

[13]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[14]  P. Vermersch,et al.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[15]  M. Epstein,et al.  Guidelines for good pharmacoepidemiology practices (GPP) , 2008 .

[16]  D. Schoenfeld,et al.  Sample-size formula for the proportional-hazards regression model. , 1983, Biometrics.

[17]  M. Sormani,et al.  Cladribine vs other drugs in MS Merging randomized trial with real-life data , 2022 .